Citations

Clear

1053 citation(s) found for "Andre, F".

Factors associated with sleep disturbance in breast cancer survivors over time
Marell, Paulina S. , Vierkant, Robert A. , Larson, Nicole L. , Ehlers, Shawna L. , Donovan, Kristine A. , D’Andre, Stacy D, Couch, Fergus J. , Ruddy, Kathryn J. , D'Andre, Stacy D, Ruddy, Kathryn J , Vierkant, Robert A , Stan, Daniela , Couch, Fergus J. , Olson, Janet E.

Mayo Clinic

The Oncologist | September 20, 2025 | Volume: 30 | Issue: 10 | Pages: No page available

10.1093/oncolo/oyaf297 | PMID 40974175 Get It

Abstract Background Breast cancer (BC) survivors frequently experience sleep disturbances, which may persist for many years after treatment. This study aimed to describe trends in sleep-related symptoms over time and identify factors that may be associated with sleep disturbances in BC survivors. Patients and Methods Adult patients from the Mayo Clinic Breast Disease Registry were surveyed annually for up to 7 years post-diagnosis. Sleep disturbance severity was assessed using numeric rating scales for difficulty falling and staying asleep. Data from 3354 unique patients were analyzed, excluding those with metastatic disease or recurrence. Univariable and multivariable analyses were performed at the 1-year survey timepoint to evaluate disease and patient-related factors that were associated with increased sleep-related symptoms, and these factors were also assessed in relationship to sleep-related symptoms over time. Results In multivariable analyses, more trouble falling asleep was associated with financial insecurity, higher clinical stage, more cigarettes smoked per day, and less weekly exercise. More trouble staying asleep was associated with older age, race, advanced education, financial insecurity, and higher clinical stage. Over time, there was a nonsignificant trend toward increased trouble falling asleep and fluctuations in trouble staying asleep. Higher clinical stage and receipt of radiotherapy were associated with decreased severity in trouble falling asleep over time, while more cigarettes smoked per day was linked to increased severity in trouble staying asleep. Conclusions These findings highlight the complex interplay of clinical, lifestyle, and demographic factors in sleep disturbances among BC survivors, underscoring the need for tailored sleep management strategies.
Five-Year Outcomes from Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson Disease
Starr, Philip A. , Shivacharan, Rajat S. , Goldberg, E. Matilda, Tröster, Alexander I. , House, P.A. , Giroux, Monique, Hebb, Adam O. , Whiting, Donald, Leichliter, Timothy, Ostrem, Jill L. , Metman, Leo Verhagen , Karl, Jessica , Siddiqui, Mustafa , Haq, Ihtsham , Moguel‐Cobos, Guillermo , Ponce, Francisco A. , Pahwa, Rajesh, Lyons, Kelly , Buetefisch, Cathrin M. , Luca, Corneliu , Jagid, Jonathan , Revuelta, Gonzalo J. , Takács, István , Pourfar, Michael , Mandybur, George, Zadikoff, Cindy , Khandhar, Suketu M., Sedrak, Mark , Phibbs, Fenna T., Neimat, Joseph S. , Durphy, Jennifer, Ramirez‐Zamora, Adolfo , Pilitsis, Julie G. , Uitti, Ryan J. , Wharen, Robert E. , Park, Michael C. , Vitek, Jerrold L. , Group, INTREPID Study, Galifianakis, Nicholas B. , Schrock, Lauren E. , Farris, Sierra, Nazzarro, Jules M., Haq, Ihtsham , Ramirez-Zamora, Adolfo , Goldberg, Edward, Sani, Sepehr , Tatter, Stephen B. , Machado, André G. , Gostkowski, Michał , Tagliati, Michele , Mamelak, Adam N. , Okun, Michael S. , Foote, Kelly D. , Pahwa, Rajesh , Gross, Robert E. , Takacs, Istvan, Mogilner, Alon Y. , Duker, Andrew , Rosenow, Joshua M. , Group, INTREPID Study, Luciano, Marta San , Cooper, Scott E.

Mayo Clinic

JAMA Neurology | September 15, 2025 | Volume: 82 | Issue: 11 | Pages: 1181

10.1001/jamaneurol.2025.3373 | PMID 40952750 Get It

Importance The Implantable Neurostimulator for the Treatment of Parkinson’s Disease (INTREPID) trial was a randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of Parkinson disease (PD). Objective To evaluate the long-term (5-year) outcomes and safety of STN-DBS for PD. Design, Setting, and Participants This was a prospective, randomized (3:1), 12-week double-blind sham-controlled study at 23 movement disorder centers across the US with an open-label 5-year follow-up. Patients were implanted and followed up with the Vercise DBS system from May 2013 to December 2022. Eligibility required diagnosis of bilateral idiopathic PD with more than 5 years of motor symptoms, more than 6 hours per day of poor motor function, modified Hoehn and Yahr Scale scores higher than 2, Unified Parkinson’s Disease Rating Scale (UPDRS-III) score of 30 or higher (medication-off state), and 33% or higher improvement in UPDRS-III medication-on score. Intervention Bilateral STN-DBS for moderate to advanced PD. Main Outcomes and Measures Primary outcomes included changes in UPDRS and dyskinesia scores, quality-of-life measures, and safety assessments. Exploratory analyses included medication reduction and DBS association with motor signs. Results A total of 313 patients were enrolled with 191 receiving the DBS system, and 137 participants (72%) completed the study. The study population had a mean (SD) age of 60 (7.9) years, with 139 (73%) male participants. Motor function without medication as measured by UPDRS-III improved from a mean (SD) of 42.8 (9.4) to 21.1 (10.6) at year 1 (51%; 95% CI, 49%-53%; P < .001) and 27.6 (11.6) at year 5 (36%; 95% CI, 33%-38%; P < .001). Activities of daily living without medication as measured by UPDRS-II improved from a mean (SD) of 20.6 (6.0) to 12.4 (6.1) at year 1 (41%; 95% CI, 38%-42%; P < .001) and 16.4 (6.5) at year 5 (22%; 95% CI, 18%-23%; P < .001). Dyskinesia scores decreased from 4.0 (5.1) to 1.0 (2.1) at year 1 (75%; 95% CI, 73%-75%; P < .001) and to 1.2 (2.1) at year 5 (70%; 95% CI, 63%-75%; P < .001). The levodopa equivalent dose was reduced by 28% at year 1, remaining stable at year 5 (28%; 95% CI, 26%-31%; P < .001). The most common serious adverse event was infection (9 participants). Ten deaths were reported, none related to the study. Conclusions and Relevance Although STN-DBS outcomes declined slightly, possibly due to the progressive nature of the disease, patients with PD sustained significant improvement in motor and activities of daily living scores, along with a stable reduction in anti-parkinsonian medication over the 5-year follow-up period.
Association between physician specialty and first-attempt intubation success in the emergency department
Besen, Bruno Adler Maccagnan Pinheiro , Carvalho, Julia M. Dorn de, Pedrollo, Daniel, Nogueira, Caio Goncalves, Figueiredo, Natalia Mansur P., Martins, Danilo, Baumgratz, Thiago Dias , Bergesch, Bruno, Costa, Diogo , Colleoni, Osmar , Zanettini, Juliana, Freitas, Ana Paula, Moreira, Nicole Pinheiro, Gaspar, Patrícia Lopes, Tambelli, Renato, Costa, Maria Cristina , Silveira, Samara, Correia, Wilsterman, Maria, Rafael Garcia de, Filho, Ubirajara A. Vinholes, Weber, Andre P., Castro, Vinicius da Silva, Dornelles, Carlos Fernando Drumond, Tabach, Barbara S., Stanzani, Gabriela , Gava, Thiago F., Silva, Gabriella Rennisy de Sousa , Oliveira, Giovanna Cardoso de, Bellolio, Fernanda , Alencar, Júlio César Garcia de , Maia, Ian Ward Abdalla , Investigators, on behalf of BARCO, Oliveira J E Silva, Lucas , Mullan, Aidan, Sandefur, Benjamin J. , Ward A Maia, Ian, Bellolio, M Fernanda , Besen, Bruno Amp , Silva, Lucas Oliveira J. e , Hellmann, Rafael von , Carvalho, Julia M. Dorn de, Hajjar, Ludhmila Abrahão , Miranda, Carlos Henrique , Tambelli, Renato, Guimarães, Hélio Penna , Mullan, Aidan F. , Oliveira, Giovanna Cardoso de, Investigators, on behalf of BARCO

Mayo Clinic

European Journal of Emergency Medicine | September 10, 2025 | Volume: 32 | Issue: 6 | Pages: 430-436

10.1097/mej.0000000000001276 | PMID 40928066 Get It

Background and importance Emergency airway management in the emergency department (ED) is a high-risk procedure associated with patient outcomes. First-attempt success is a widely recognized quality metric, as multiple attempts are associated with an increased risk of peri-intubation complications. In Brazil, where emergency medicine is a recently established specialty, many ED are staffed by physicians without formal emergency medicine training. The association between emergency medicine training and intubation outcomes in this setting has not been well characterized. Objective To assess the association of physician specialty with first-attempt success and immediate peri-intubation complications in Brazilian EDs. Design Secondary analysis of a multicenter, prospective cohort study from the Brazilian Airway Registry Cooperation. Setting and participants This study included adult patients who underwent tracheal intubation in EDs between March 2022 and April 2024. Patients were excluded if the intubation occurred outside the ED, during cardiopulmonary resuscitation, or for elective procedures. Intubations performed by medical students were also excluded. Physicians were categorized by specialty as emergency medicine or nonemergency medicine. Outcome measures and analysis The primary outcome was first-attempt success; secondary outcomes included peri-intubation complications (severe hypoxemia, hemodynamic instability, and cardiac arrest). Multivariable logistic regression was used to assess the association between physician specialty and outcomes. Main results Among 2582 patients, 1087 (42.1%) were intubated by emergency physicians and 1495 (57.9%) by other physicians (mainly internal medicine and surgery). Intubations by emergency physicians were associated with a higher rate of first-attempt success [80.4 vs. 70.9%, adjusted odds ratio [aOR]: 1.63, 95% confidence interval (CI): 1.34–1.97]. There was also a higher odds of intubations without major complications (aOR: 1.20, 95% CI: 1.01–1.42). Conclusion In this study, there was a higher rate of first-attempt success in intubations performed by board-certified emergency physicians compared with other physicians working in Brazilian EDs.
Genetic risk factors modulate the association between physical activity and colorectal cancer
Kim, Andre E., Fu, Yubo, Morrison, John, Lin, Yi, Berndt, Sonja, Chang-Claude, Jenny, Conti, David V., Corley, Douglas A. , Gruber, Stephen B. , Harlid, Sophia , Huyghe, Jeroen R. , Kundaje, Anshul , Martín, Vicente , Newton, Christina C. , Hardikar, Sheetal , Pai, Rish K. , Papadimitriou, Nikos , Pinchev, Mila, Schoen, Robert , Tsilidis, Konstantinos K, Duijnhoven, Franzel J. B. van, Visvanathan, Kala , Wolk, Alicja, Woods, Michael O. , Wu, Anna H. , Ulrich, Cornelia M. , Peters, Ulrike, Gauderman, W. James, Moreno, Victor, Martín, Vicente , Drew, David A. , Martín, Vicente , Drew, David A , Visvanathan, Kala , Kundaje, Anshul , Papadimitriou, Nikos , Peoples, Anita R , Obón‐Santacana, Mireia , Kawaguchi, Eric , Qu, Conghui , Moratalla-Navarro, Ferrán , Morrison, John, Arndt, Volker , Bien, Stephanie A. , Bishop, D. Timothy , Bouras, Emmanouil , Brenner, Hermann , Buchanan, Daniel D. , Campbell, Peter T. , Chan, Andrew T. , Chang‐Claude, Jenny , Conti, David V. , Devall, Matthew A M , Dimou, Niki , Gunter, Marc J. , Harrison, Tabitha A. , Hoffmeister, Michael , Hsu, Li , Keku, Temitope O , Lewinger, Juan Pablo , Lynch, Brigid M , Marchand, Loı̈c Le , Murphy, Neil , Ogino, Shuji , Ose, Jennifer , Palmer, Julie R. , Pardamean, Bens , Pellatt, Andrew J. , Platz, Elizabeth A. , Potter, John D. , Rennert, Gad , Ruiz-Narvaez, Edward , Sakoda, Lori C. , Schoen, Robert E., Shcherbina, Anna, Stern, Mariana Carla , Su, Yu-Ru , Thomas, Claire E. , Tian, Yu , Tsilidis, Konstantinos K. , Um, Caroline Y. , Guelpen, Bethany Van , Wang, Jun, White, Emily , Wolk, Alicja , Peters, Ulrike, Gauderman, W. James

Mayo Clinic

No container title available | September 2, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7350654/v1 | PMID 40951278 Get It

Abstract Background Physical activity (PA) is an established protective factor for colorectal cancer (CRC), but it is unclear if genetic variants modify this effect. To investigate this possibility, we conducted a genome-wide gene–PA interaction analysis. Methods Using logistic regression and two-step and joint tests, we analyzed interactions between common genetic variants across the genome and PA in relation to CRC risk. Self-reported PA levels were categorized as active (≥ 8.75 MET-h/wk) vs. inactive (< 8.75 MET-h/wk) and as study- and sex-specific quartiles of activity. Results PA had an overall protective effect on CRC (OR [active vs. inactive] = 0.85; 95%CI = 0.81–0.90). The two-step GxE method identified an interaction between rs4779584, an intergenic variant near the GREM1 and SCG5 genes, and PA for CRC risk (p-interaction = 2.6×10 − 8 ). Stratification by genotype at this locus showed a significant reduction in CRC risk by 20% in active vs. inactive participants with the CC genotype (OR = 0.80; 95%CI = 0.75–0.85), but no significant PA–CRC association among CT or TT carriers. When PA was modeled as quartiles, the 1-d.f. GxE test identified that rs56906466, an intergenic variant near the KCNG1 gene, modified the association between PA and CRC (p-interaction = 3.5×10 − 8 ). Stratification at this locus showed that increase in PA (highest vs. lowest quartile) was associated with a lower CRC risk solely among TT carriers (OR = 0.77; 95%CI = 0.72–0.82). Conclusions In summary, we identified two genetic variants that modified the association between PA and CRC risk. One of them, related to GREM1 and SCG5 , suggests that the bone morphogenetic protein (BMP)-related, inflammatory, and/or insulin signaling pathways may be associated with the protective influence of PA on colorectal carcinogenesis.
Effect of peri‐operative pharmacological interventions on postoperative delirium in patients having cardiac surgery: a systematic review and Bayesian network meta‐analysis
Queiroz, Ivo , Tavares, Arthur, Pimentel, Túlio , Righetto, Bruno Branco , Tong, Guangyu , Ferreira Félix, Iuri, Barbosa, Lucas , Ruelas, Mariano Gallo , Araújo, Beatriz, Defante, Maria Luiza Rodrigues , Mesquita, Cynthia Florêncio de , Mendes, Beatriz Ximenes , Félix, Iuri Ferreira , Rivera, André , Ferreira, Rafael Oliva Morgado , Oliveira, Helen Michaela de , Smischney, Nathan J. , Ma, Daqing

Mayo Clinic

Anaesthesia | September 1, 2025 | Volume: 81 | Issue: 2 | Pages: 274-287

10.1111/anae.16757 | PMID 40888048 Get It

Summary Introduction Postoperative delirium is a common complication following cardiac surgery. Despite its known impact on patient outcomes, effective preventative strategies remain elusive. We aimed to perform a comprehensive Bayesian network meta‐analysis of randomised controlled trials assessing the effect of pharmacological interventions on the incidence of postoperative delirium. Methods Databases were searched from inception to September 2024. Our search was updated in January 2025. Eligible studies included randomised controlled trials reporting the incidence of postoperative delirium in patients having cardiac surgery treated with pharmacological interventions. Bayesian models were used to estimate risk ratios (RR) and mean differences with 95%CrI through Markov chain Monte Carlo. Interventions were ranked using the surface under the cumulative ranking curve. Sensitivity analyses and grading of recommendations, assessment, development and evaluation assessment were conducted to evaluate the robustness and certainty of evidence. Results Seventy‐nine randomised controlled trials comprising 24,827 patients were included, with 29 pharmacological interventions compared. Dexmedetomidine combined with melatonin was the most effective intervention, reducing the incidence of postoperative delirium compared with placebo (risk ratio 0.31, 95%CrI 0.13–0.69; low certainty). Dexmedetomidine with melatonin also significantly decreased intensive care unit stay (2.4 days, 95%CrI ‐3.50–1.10) and hospital stay (1.32 days, 95%CrI ‐2.09 to ‐0.57). Other interventions, including ketamine and risperidone, showed potential efficacy but with low or very low certainty of evidence. Discussion We identified dexmedetomidine with melatonin as the most effective pharmacological strategy for preventing postoperative delirium following cardiac surgery. Whilst these findings highlight potential benefits, the low certainty of evidence underscores the need for more high‐quality primary evidence.
High‐Power Short‐Duration Ablation Versus Conventional Power Ablation in Pulmonary Vein Isolation in Patients With Atrial Fibrillation: An Updated Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Cabral, David C. B. I. , Rivera, André , Braga, Marcelo Antonio Pinheiro , Passos, Bárbara Mariz Ferreira, Ternes, Caique M. P. , Brígido, Alexandra Régia Dantas , Carvalho, Guilherme Dagostin de , Deshmukh, Abhishek , DeSimone, Christopher V. , Ferreira Félix, Iuri, de Carvalho, Guilherme Dagostin , Deshmukh, Abhishek J , DeSimone, Christopher V , Ternes, Caique M P , Félix, Iuri Ferreira , Rivera, A

Mayo Clinic

Journal of Cardiovascular Electrophysiology | August 31, 2025 | Volume: 36 | Issue: 10 | Pages: 2620-2628

10.1111/jce.16735 | PMID 40886137 Get It

ABSTRACT Background High‐power short‐duration (HPSD) ablation has emerged as a promising alternative to conventional power delivery (CPD) for pulmonary vein isolation (PVI) among patients with atrial fibrillation (AF), though its efficacy, procedural efficiency, and safety profile remain uncertain. Aims To evaluate and compare the efficacy, procedural efficiency, and safety of HPSD versus CPD ablation strategies for PVI in patients with AF through a systematic review and meta‐analysis of randomized controlled trials (RCTs). Materials and Methods PubMed, Embase, Cochrane Library, and ClinicalTrials.Gov databases were systematically searched for RCTs comparing HPSD with CPD ablation for PVI in patients with AF. Random‐effects models were used to pool hazard ratios (HR) and risk ratios (RR) with 95% confidence intervals (CI). R version 4.4.2 was used for statistical analysis. Results Eight RCTs with 1094 patients (558 undergoing HPSD and 536 undergoing CPD ablation) were included. No significant differences were found in freedom from arrhythmia during the follow‐up period (HR: 0.77; 95% CI: 0.41–1.45; p = 0.424). AF recurrence did not differ (RR: 0.83; 95% CI: 0.59–1.16; p = 0.268) between groups. HPSD had a significantly shorter procedural (mean difference [MD]: −21.93 min; 95% CI: −31.34, −12.53; p < 0.001) and RF ablation times (MD: −13.87 min; 95% CI: −19.46, −8.27; p < 0.001). No differences were observed in fluoroscopy time and first‐pass isolation for right and left pulmonary veins. There was no difference in esophageal lesion rates, pericardial, or neurological complications, but there was a higher incidence of steam pops in HPSD (RR: 3.42; 95% CI: 1.45–8.09; p = 0.005). Discussion Although HPSD ablation did not significantly improve freedom from arrhythmia or reduce AF recurrence compared to CPD, it demonstrated enhanced procedural efficiency, with shorter procedure and RF ablation times. Despite the higher rate of steam pops, the overall safety profile was similar between both groups. Conclusion High‐power short‐duration ablation for pulmonary vein isolation in atrial fibrillation demonstrated comparable efficacy and safety to conventional power delivery, with the added benefit of shorter procedure and RF ablation times. However, HPSD ablation was associated with increased occurrence of steam pops.
Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia
Fortuna, Gliceida Galarza , Peres, Lauren C. , Corraes, Andre De Menezes Silva , Hovanky, Vanna, Shune, Leyla , McGuirk, Joseph P. , Avilla, Gabriel De, Khouri, Jack , Dima, Danai , Gaballa, Mahmoud , Dhakal, Binod , Forsberg, Peter A. , Godara, Amandeep , Afrough, Aimaz , Anderson, Larry D. , Davis, James A. , Mann, Hashim , Purvey, Sneha , Clark, William , Htut, Myo, Ferreri, Christopher J. , Voorhees, Peter M. , Hashmi, Hamza , Patel, Krina K. , Sidana, Surbhi , Lin, Yi, Sborov, Douglas W. , Galarza Fortuna, Gliceida M , De Menezes Silva Corraes, Andre , McGuirk, Joseph , Khouri, Jack , Dima, Danai , Dhakal, Binod , Godara, Amandeep , Anderson, Larry D , Herr, Megan M. , Davis, James A , Mann, Hashim , Kocoglu, Mehmet H , Voorhees, Peter , Patel, Krina , Sidana, Surbhi , Hansen, Doris K , Sborov, Douglas W , Назаренко, Елена Борисовна , Avilla, Gabriel De, Clark, William, Htut, Myo , Beitinjaneh, Amer , Pereira, Denise L. , Kocoglu, Mehmet H. , Atrash, Shebli , Rossi, Adriana , Richard, Shambavi , Hansen, Doris K.

Mayo Clinic

Blood Advances | August 28, 2025 | Volume: 9 | Issue: 23 | Pages: 6009-6018

10.1182/bloodadvances.2025016966 | PMID 40875887 Get It

Abstract Despite significant therapeutic advances in multiple myeloma (MM), outcomes in patients with plasma cell leukemia (PCL) remain dismal. We conducted a multicenter retrospective analysis of patients with PCL who were treated with the B-cell maturation antigen–directed chimeric antigen receptor T-cell (CAR-T) products idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). We identified 34 patients; 19 patients received ide-cel and 15 received cilta-cel. With a median follow-up of 11.9 months, the overall median progression-free survival (mPFS) was 9.0 months (95% confidence interval [CI], 4-15) and the median overall survival (mOS) was 13.0 months (95% CI, 8 to not estimable [NE]). The 1-year cumulative incidence of progression or death was 72%, and the 1-year cumulative incidence of death was 47%. Patients who received cilta-cel had a longer mPFS (19.0 months vs 6.0 months) and mOS (&gt;23 months [NE] vs 9.0 months) when compared with those treated with ide-cel. Similarly, the 1-year cumulative incidence of disease progression or death was 37.5% (95% CI, 17.4-68.5) with cilta-cel, whereas all patients treated with ide-cel progressed or died within 12 months of infusion. The rates of hematologic and nonhematologic toxicities were similar between patients treated with cilta-cel and those treated with ide-cel and were consistent with those reported in patients with MM. In this first multicenter study that evaluated patients with PCL who were treated with standard-of-care CAR-T products, we show that CAR-T is safe, feasible, and associated with improved outcomes when compared with historic standards.
Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study
Herrera, Alex F. , Ansell, Stephen M. , Zinzani, Pier Luigi , Maddocks, Kami J. , Pinto, Antonio , Collins, Graham P. , Bachanová, Veronika , Bartlett, Nancy L. , Bence‐Bruckler, Isabelle , Mayer, Jiří , Advani, Ranjana H. , Feldman, Tatyana , Hess, Brian , Szomor, Árpád, André, Marc, Dyczkowski, Jerzy, Havenith, Karin , Toukam, Marie , Pantano, Serafino, Cruz, Hans G. , Wang, Luqiang, Negievich, Yanina, Lucero, Melanie , Wuerthner, Jens, Carlo‐Stella, Carmelo , Radford, John , Pinto, Antonio , Bartlett, Nancy L , Hamadani, Mehdi , Savage, Kerry J , Casasnovas, René-Olivier , Iyengar, Sunil , Townsend, William , Cruz, Hans G , Carlo-Stella, Carmelo , Bachanova, Veronika , Zinzani, Pier Luigi , Advani, Ranjana H , Radford, John , Collins, Graham P., Hamadani, Mehdi , Kline, Justin Paul , Savage, Kerry J. , Caimi, Paolo F. , Casasnovas, Olivier , Bastos‐Oreiro, Mariana , Townsend, William

Mayo Clinic

Blood Advances | August 14, 2025 | Volume: 9 | Issue: 23 | Pages: 6205-6217

10.1182/bloodadvances.2024015600 | PMID 40811783 Get It

Abstract Outcomes in classic Hodgkin lymphoma (cHL) have steadily improved; however, additional therapies are needed for patients who relapse or do not respond to novel agents. Here, we report the efficacy and safety of camidanlumab tesirine (Cami), an anti-CD25 antibody-drug conjugate, in patients with relapsed/refractory cHL after brentuximab vedotin/programmed cell death protein 1 inhibitor therapies from the phase 2 ADCT-301-201 study. Eligible patients were adults with cHL who had received ≥3 previous lines of systemic therapy (or ≥2 if ineligible for hematopoietic stem cell transplant). Patients received 45 μg/kg Cami (IV, once every 3 weeks) in cycles 1 to 2, followed by 30 μg/kg IV once every 3 weeks for ≤1 year. The primary end point was overall response rate (ORR) per 2014 Lugano classification. Secondary end points included complete response rate (CRR), progression-free survival (PFS), and overall survival (OS). In total, 117 patients were enrolled with a median age of 37.0 years (range, 19-87). The ORR was 70.1% (95% confidence interval [CI], 60.9-78.2), with a CRR of 33.3% (95% CI, 24.9-42.6). The median PFS was 9.13 months (95% CI, 5.3-15.0); median OS was not reached. Thirty-three (28.2%) patients discontinued treatment because of treatment-emergent adverse events; the most common reasons were skin and subcutaneous tissue disorders (n = 10 [8.5%] patients), infections and infestations (n = 5 [4.3%]), and nervous systems disorders (n = 5 [4.3%]). Guillain-Barré–type or polyradiculopathy-type events occurred in 8 (6.8%) patients. Cami was efficacious in this heavily pretreated population; however, the efficacy was overshadowed by substantial issues with the safety profile. This trial was registered at www.clinicaltrials.gov as #NCT04052997.
Sequence variability of BamA and FadL candidate vaccinogens suggests divergent evolutionary paths of Treponema pallidum outer membrane proteins
Bettin, Everton B. , Aghakhanian, Farhang , Hennelly, Christopher M. , Chen, Wentao , Davenport, Timothy C. , Hackl, Simon T. , Grassmann, André Alex , Vargas-Cely, Fabio Samir , Silva, Sebastián , Luna, Jonny Alejandro García , Jiang, Yinbo , Yang, Ligang , Zheng, Heping , Pospíšilová, Petra , Šmajs, David , Matoga, Mitch , Hoffman, Irving , Moody, M. Anthony , Salazar, Juan C. , Radolf, Justin D. , Vargas-Cely, Fabio, Šmajs, David , Caimano, Melissa J , Hawley, Kelly L , Radolf, Justin D , Ramirez, Lady Giovanna , Yang, Bin , López‐Medina, Eduardo , Nieselt, Kay , Seña, Arlene C. , Parr, Jonathan B.

Mayo Clinic

Journal of Bacteriology | July 14, 2025 | Volume: 207 | Issue: 8 | Pages: No page available

10.1128/jb.00159-25 | PMID 40802283 Get It

ABSTRACT Knowledge of Treponema pallidum subspecies pallidum ( TPA ) outer membrane protein (OMP) sequence variability is essential for understanding spirochete proliferation within endemic populations as well as the design of a globally effective syphilis vaccine. Our group has identified extracellular loops (ECLs) of TPA BamA (TP0326) and members of the FadL family (TP0548, TP0856, TP0858, TP0859, and TP0865) as potential components of a multivalent vaccine cocktail. As part of a consortium to explore TPA strain diversity, we mapped the variability of BamA and FadL orthologs in 186 TPA strains from Malawi, China, and Colombia onto predicted 3D structures. The 186 genomes fell into eight subclades (five Nichols- and three SS14-lineage) with substantial geographic restriction. Single nucleotide variants accounted for the large majority of proteoforms, with variability notably higher within the Nichols-lineage strains. Most mutations were in regions of the proteins predicted to be extracellular and harboring B cell epitopes. We observed a striking difference in the degree of variability between the six OMPs, suggesting that these proteins are following divergent evolutionary paths. Concatenation of OMP sequences recapitulated the phylogenetic structure of the TPA strains, effectively segregating within clades and largely clustering by subclades. Finally, we noted that BamA and FadL candidate ECL vaccinogens, previously shown to elicit antibodies that kill treponemes during in vitro cultivation, are well conserved. Taken as a whole, our study establishes a structural-phylogenetic approach for analyzing the forces shaping the host-pathogen interface in syphilis within endemic populations while informing the selection of vaccine targets. IMPORTANCE Syphilis remains a major global health concern, reinforcing the need for a safe and effective vaccine. Understanding the variability of TPA OMPs is essential for tracking pathogen evolution and informing vaccine design. Here, we analyzed the variability of six TPA OMPs in 186 strains from Malawi, China, and Colombia, identifying protein-specific evolutionary patterns. Most mutations were localized in extracellular regions and, notably, appeared to correlate with the phylogenetic structure of TPA . Despite OMP heterogeneity, several candidate vaccinogens remained highly conserved, reinforcing their potential as globally effective vaccine targets. Our study establishes a structural-phylogenetic framework for dissecting the forces shaping the host-spirochete interface within endemic populations and provides a foundation for designing a globally effective syphilis vaccine.
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Razzo, Beatrice M. , Midha, Shonali , Portuguese, Andrew J. , Grajales‐Cruz, Ariel , Corraes, Andre De Menezes Silva , Costello, Patrick , Liu, Yuxin , Sperling, Adam S. , Nadeem, Omar , Dima, Danai , Cowan, Andrew J. , Afrough, Aimaz , Anderson, Larry D. , Goyal, Anmol , Ferreri, Christopher J. , Voorhees, Peter M. , Patel, Krina K. , Julian, Kelley , Forsberg, Peter A. , Susanibar-Adaniya, Sandra P. , Khouri, Jack , Raza, Shahzad , Vazquez‐Martinez, Mariola , Sborov, Douglas W. , Davis, James A. , Shune, Leyla , Bhurtel, Jenny , Hwang, Wei‐Ting , Sidana, Surbhi , Grajales-Cruz, Ariel F , De Menezes Silva Corraes, Andre , Banerjee, Rahul , Cowan, Andrew J , Afrough, Aimaz , Anderson, Larry D , Lieberman-Cribbin, Alex , Kaur, Gurbakhash , Goyal, Anmol , Atrash, Shebli , Ferreri, Christopher , Voorhees, Peter , Pasvolsky, Oren , Lee, Hans C , Patel, Krina , Julian, Kelley L , Forsberg, Peter A , Herr, Megan M. , Chhabra, Saurabh , Parrondo, Ricardo D , Lin, Yi , Chen, Anna , Susanibar-Adaniya, Sandra P , Khouri, Jack , Raza, Shahzad , Anwer, Faiz , Vazquez-Martinez, Mariola A , Castaneda Puglianini, Omar , Sborov, Douglas W , Davis, James A , Rossi, Adriana , Shune, Leyla , Bhurtel, Evguenia , Hwang, Wei-Ting , Hansen, Doris K , Sidana, Surbhi , Garfall, Alfred L , Richard, Shambavi , Nadeem, Omar , Dima, Danai , Sperling, Adam S , Portuguese, Andrew J , Banerjee, Rahul , Kaur, Gurbakhash , Atrash, Shebli , Pasvolsky, Oren , Lee, Hans C. , Chhabra, Saurabh , Lin, Yi , Anwer, Faiz , Puglianini, Omar Castañeda , Rossi, Adriana , Hansen, Doris K. , Garfall, Alfred L. , Richard, Shambavi

Mayo Clinic

Blood Cancer Discovery | July 9, 2025 | Volume: 6 | Issue: 6 | Pages: 561-571

10.1158/2643-3230.bcd-24-0354 | PMID 40629516 Get It

Abstract Teclistamab is an anti-CD3-/B-cell maturation antigen (BCMA) bispecific antibody approved for use in relapsed/refractory multiple myeloma. We undertook a retrospective study of post-approval, real-world outcomes with teclistamab in the US Multiple Myeloma Immunotherapy Consortium. Among 509 patients, 89% would have been ineligible for the MajesTEC-1 trial, primarily due to prior BCMA-directed therapy, cytopenias, or diminished performance status. Cytokine release syndrome occurred in 54% (1.4% grade ≥3) and immune effector cell–associated neurotoxicity syndrome in 11% (2.2% grade ≥3), with no fatal events. Infections occurred in 42% and contributed to death in 5%. Partial response (PR) or better was achieved in 53% and very good PR or better in 45%. With 10.1 months of median follow-up, the estimated median progression-free survival (PFS) was 5.8 months and 12-month overall survival was 61%. Independent predictors of less than very good PR and shorter PFS included BCMA-directed chimeric antigen receptor T-cell therapy in the previous 9 months, high disease burden, lymphopenia, and elevated ferritin. Significance: T cell–engaging bispecific antibodies such as teclistamab represent an important new treatment modality for multiple myeloma and other blood cancers. This study evaluates the real-world safety and efficacy of teclistamab, including its activity in populations not represented in the initial phase I/II study, and identifies clinical variables associated with treatment response. See related commentary by Zweegman et al., p. 542